Pfizer-BioNTech COVID-19 vaccine : standing orders for administering vaccine to persons 16 years of age and older
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i

Pfizer-BioNTech COVID-19 vaccine : standing orders for administering vaccine to persons 16 years of age and older

Filetype[PDF-207.80 KB]


English
Details You May Also Like

Details:

  • Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
  • Description:
    On April 13, 2021, CDC and FDA recommended a pause in the use of Janssen COVID-19 Vaccine (Johnson & Johnson) out of an abundance of caution while they review data involving a small number of reports of cerebral venous sinus thrombosis (CVST) with thrombocytopenia in individuals after receiving Janssen COVID-19 Vaccine (https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19- vaccine). The Advisory Committee on Immunization Practices (ACIP, https://www.cdc.gov/vaccines/acip/index.html) met on April 14. After hearing additional data on these reports, ACIP agreed that more information is needed before policy recommendations can be made regarding continued use of the Janssen COVID-19 vaccine. CDC will collect more information and convene another ACIP meeting on April 23 to review any additional scientific evidence.

    At this time, the recommended pause supersedes any other recommendations for use of Janssen COVID-19 Vaccine.

    Recommendations for clinicians related to the detection, evaluation, proper management, and reporting of cases of CVST with thrombocytopenia after receipt of Janssen COVID-19 Vaccine are outlined in Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States at https://www.cdc.gov/vaccines/covid-19/info- by-product/clinical-considerations.html. These can also be found in CDC’s Health Alert (https://emergency.cdc.gov/ han/2021/han00442.asp) , issued April 13.

    If you are a COVID-19 vaccination provider with Janssen COVID-19 Vaccine:

    1. Mark any Janssen COVID-19 Vaccine in your inventory “Do not use. Awaiting guidance.”

    2. Continue to store the vaccine in the refrigerator between 2°C and 8°C (36°F and 46°F).

    3. Continue to monitor and document storage unit temperatures and follow recommended vaccine storage practices.

    04/19/2021 CS321570-H

    standing-orders.pdf

  • Subjects:
  • Document Type:
    Pamphlet (or booklet)
  • Name as Subject:
  • Genre:
    Fact Sheet
  • Pages in Document:
    4 numbered pages
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

Supporting Files

  • No Additional Files
More +

You May Also Like

Checkout today's featured content at stacks.cdc.gov